- $1.93bn
- $676.81m
- $548.51m
Positive Topline Results of Phase III Trial
Brief: Hutchmed Announces Positive Topline Phase III Trial Of Sovleplenib For Warm Antibody Autoimmune Hemolytic Anemia
Surufatinib + Camrelizumab PDAC Phase 3 initiation
Brief: Hutchmed (China) Says NDA For Savolitinib Accepted With Priority Review In China
China NDA Acceptance-Savolitinib in Gastric Cancer
Brief: Hutchmed (China) Says NDA For Fanregratinib Accepted With Priority Review In China
NDA Acceptance in China for Fanregratinib
HUTCHMED Initiates Development of ATTC Candidate
HUTCHMED Highlights Data at ESMO and ASH
Enrollment Complete in SAFFRON Global Phase III
Updates from R&D Event
HUTCHMED Presents Data at AACR NCI EORTC
Vesting of awards under Long Term Incentive Plan
Appointment of Independent Non-executive Director
Data to be Presented at the 2025 ESMO Congress
HUTCHMED Highlights Data to be Presented at ESMO
HUTCHMED to Present R&D Updates on October 31 2025
HUTCHMED Highlights Data to be Presented at CSCO
Directorate Change